HUMA (Humacyte, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of May 20, 2026, HUMA trades at $0.86 with a market cap of $199.46M and a P/E ratio of -1.43. HUMA moved +4.64% today. Year to date, HUMA is -15.35%; over the trailing twelve months it is -62.99%. Its 52-week range spans $0.55 to $6.77. Analyst consensus is strong buy with an average price target of $2.27. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns HUMA stock?
Hedge funds tracked by Rallies that own HUMA include Centerbook Partners and Sculptor Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Humacyte, Inc. Common Stock.
HUMA Key Metrics
Key financial metrics for HUMA
Metric
Value
Price
$0.86
Market Cap
$199.46M
P/E Ratio
-1.43
EPS
$-0.59
Dividend Yield
0.00%
52-Week High
$6.77
52-Week Low
$0.55
Volume
1.64M
Avg Volume
0
Revenue (TTM)
$2.02M
Net Income
$-97.59M
Gross Margin
-475.05%
Top Hedge Funds Holding HUMA
Centerbook Partners holds 283.63K shares of HUMA, changed -91.73% as of Sep 30, 2025.
Sculptor Capital holds 232.40K shares of HUMA, changed +0.00% as of Jun 30, 2025.
Hedge funds tracked by Rallies that own HUMA include Centerbook Partners and Sculptor Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Humacyte, Inc. Common Stock.
Does Rallies show 13F holders for HUMA?
Yes. Rallies tracks hedge fund and 13F ownership data for HUMA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HUMA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HUMA. It does not provide personalized investment advice.
